AUS
NZ
UK
CA
USA
IND
Frontier IP Group Plc (AIM: FIPP) has revealed that its portfolio company, InSignals Neurotech, has been awarded a €317,762 grant from the European Union under the Portugal 2030 framework. This funding will support the enhancement of its remote monitoring technology and the launch of a new mobile application aimed at improving management of Parkinson’s disease. This milestone underscores InSignals’ innovation potential and growth prospects within the health tech industry.
Key Points
- Company: Frontier IP Group Plc (FIPP)
- Development: InSignals Neurotech secures €317,762 EU grant
- Details: €317,762 grant under PT2030 framework
- Investor focus: Progress on app launch and remote monitoring enhancements
InSignals Neurotech Awarded EU Grant to Expand Remote Monitoring Capabilities
Frontier IP Group Plc has confirmed that InSignals Neurotech, one of its portfolio companies, has received a €317,762 grant co-financed by the European Union through the Portugal 2030 initiative, specifically via the NORTE 2030 programme. This funding highlights the company’s pioneering role in health technology innovation.
The grant will enable InSignals to adapt its proprietary algorithms for remote operation with third-party wearable devices such as smartwatches and smart rings. This advancement aims to support continuous, real-world monitoring of Parkinson’s disease symptoms beyond clinical environments, enhancing patient care and accessibility.
Development of Parkinson’s Disease Management Mobile Application
Alongside the grant, InSignals Neurotech is preparing to launch a mobile app designed to assist Parkinson’s patients and their caregivers. This project is supported by a prior grant from PRR Green Vouchers. The app will facilitate ongoing symptom tracking and improve communication between patients and healthcare providers, marking a significant expansion into patient-centered digital health solutions.
The app’s integration with popular consumer devices aligns with InSignals’ strategy to boost adoption and accessibility, enabling scalable, data-driven care and more responsive treatment adjustments.
Significance of the Portugal 2030 Framework
The Portugal 2030 framework, under which this grant was awarded, is an EU-backed programme designed to foster Portugal’s economic, social, and territorial development, with a strong emphasis on innovation and digital technologies. This support validates InSignals’ technological advancements and positions the company for future growth.
For investors, this alignment with EU priorities signals promising prospects for InSignals as it contributes to advancements in healthcare technology.
Integration with Advanced Parkinson’s Therapies
InSignals’ technology is engineered to integrate with advanced treatments, including deep brain stimulation (DBS) and potentially infusion-based drug therapies. This capability enhances its value proposition by offering comprehensive management solutions for Parkinson’s disease.
Such integration supports more personalized and effective treatment plans, benefiting both patients and healthcare providers, while potentially opening new revenue opportunities for InSignals.
Seed Fundraising and Global Expansion Efforts
The company is currently conducting a seed fundraising round to support medical regulatory compliance and international growth. InSignals is engaging investors who could leverage Portugal’s co-investment programmes and favourable innovation funding environment.
This capital raising is vital for accelerating InSignals’ expansion and strengthening its position in the global health technology market.
Clinical Validation and Intellectual Property
InSignals’ technology has been rigorously validated in an international multi-centre clinical study involving over 200 patients, demonstrating its reliability and effectiveness in real-world applications.
As a pioneer in objective rigidity measurement, InSignals holds patents on rigidity quantification methods, providing a strong competitive advantage and a foundation for future innovation.
Industry Recognition and Collaborations
InSignals Neurotech has earned recognition as one of Portugal’s leading health technology companies. It was named a top HealthTech startup for 2025 by F6S and was previously selected as a "One to Watch" in the Nature Spin-Off Prize 2020.
The company’s active participation in multi-centre clinical studies across Portugal, the Netherlands, and Spain, along with its engagement with industry partners, highlights its commitment to advancing healthcare solutions and enhancing its reputation to attract further investment.
Leadership and Founding Vision
Founded to commercialise research by Professor João Paulo Cunha, a Full Professor at the University of Porto’s Faculty of Engineering and Senior Researcher at INESC TEC, InSignals embodies his vision of merging rigorous clinical science with accessible digital technology.
The leadership team’s dedication to revolutionising Parkinson’s disease management through innovative technology is central to the company’s ongoing success and strategic direction.
